Copyright
©The Author(s) 2022.
World J Stem Cells. Jul 26, 2022; 14(7): 503-512
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.503
Published online Jul 26, 2022. doi: 10.4252/wjsc.v14.i7.503
Cell types | Advantages | Disadvantages | Ref. |
Embryonic stem cell | High degree of differentiation | ESCs is weak in directional differentiation and difficult to induce | [35,36] |
There are ethical issues: ESCs are usually allogeneic | |||
Teratoma, immune rejection and gene mutation may occur after transplantation | |||
Induced pluripotent stem cell | IPSC technology does not use embryonic or egg cells, so ethical problems are less likely | At present, the differentiation scheme of induced pluripotent stem cells is not mature, and the induction efficiency is low, the stability is poor, and the cost is high | [39] |
Proprietary stem cells can be made from a patient's own cells, so there is less immune rejection | The use of virus vectors poses security problems | ||
Adult stem cell | It is easy to achieve targeted differentiation, and some studies have shown that adult stem cells can be used to treat diabetes | The direction of differentiation is limited, not omnipotent | [43,44] |
After transplantation, the ability of induced differentiated cells to secrete insulin was usually lower than that of normal islet β cells, and the cell survival rate was also lower | |||
The efficiency of inducing differentiation at different stages is still low based on reprogramming and small molecule screening |
- Citation: Yang L, Hu ZM, Jiang FX, Wang W. Stem cell therapy for insulin-dependent diabetes: Are we still on the road? World J Stem Cells 2022; 14(7): 503-512
- URL: https://www.wjgnet.com/1948-0210/full/v14/i7/503.htm
- DOI: https://dx.doi.org/10.4252/wjsc.v14.i7.503